礼来公司宣布收购Organovo旗下的FXR项目及其主打疗法FXR314,这是一款用于治疗溃疡性结肠炎等疾病的潜在“best-in-class”口服FXR小分子激动剂。Organovo已获得美国FDA的临床试验许可,正在进行2期试验,并计划将其应用于 ...
智通财经APP获悉,Organovo Holdings今日宣布,礼来(LLY.US)(Eli Lilly and ...
全球制药巨头礼来近日宣布以4.5亿美元收购Organovo的FXR项目,这项交易不仅创下2025年开年最大生物技术并购案,更折射出药物研发领域正在经历范式转移。在传统新药研发成功率持续低迷的背景下(2024年Nature数据显示临床阶段药物失败率仍高达85%),Organovo凭借其革命性的3D生物打印技术平台,成功推动FXR314在溃疡性结肠炎等适应症上展现出best-in-class潜力。这场 ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前,Organovo已获得美国FDA的临床试验许可,正在进行其主打疗法FXR314用于治疗溃疡性结肠炎(UC)的2期试验。公司通过其专有的3D人体组织模型,制定了针对FX ...
圣地亚哥 - 专注于3D人体组织模型的生物科技公司Organovo Holdings, Inc. (NASDAQ: ONVO )已达成协议,将其FXR项目(包括主要资产FXR314)出售给制药巨头礼来公司 (NYSE: LLY )。礼来目前市值达到7,940亿美元,股价交易价格高于InvestingPro公平价值。这项交易标志着炎症性肠病 (IBD)治疗领域的重要进展。
Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.
Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Industrials/Producer Durables AlphaDEX ETF (FXR) provides investors broad exposure to the Industrials ETFs category of the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果